Die neuen ANTI-VEGF Präparate: Evolution oder Revolution?

Die IVOM-Therapie gehört zu den wichtigsten Säulen in der Behandlung vieler ophthalmologischer Erkrankungen, allen voran der neovaskulären altersbedingten Makuladegeneration (nAMD) und des diabetischen Makulaödems (DMÖ).

Publikationsverlauf

Artikel online veröffentlicht:
05. Februar 2025

• Literatur

• 1 Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol 2016; 10: 939-946
• 2 Berg K, Pedersen TR, Sandvik L. et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015; 122: 146-152
• 3 Ohji M, Takahashi K, Okada AA. et al. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial. Adv Ther 2020; 37: 1173-1187
• 4 Mitchell P, Holz FG, Hykin P. et al. Efficacy and Safety of Intravitreal Aflibercept Using a Treat-and-Extend Regimen for Neovascular Age-related Macular Degeneration: The ARIES Study: A Randomized Clinical Trial. Retina 2021; 41: 1911-1920
• 5 Dugel PU, Singh RP, Koh A. et al. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 2021; 128: 89-99
• 6 Khanani AM, Kotecha A, Chang A. et al. TENAYA and LUCERNE: 2-Year Results from the Phase 3 nAMD Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology 2024; 131: 914-926
• 7 Regeneron Pharmaceuticals. Two-year PULSAR trial results for aflibercept 8 mg demonstrate durable vision gains at extended dosing intervals in wet age-related macular degeneration (August 2023). Im Internet (Stand: 01.03.2024): https://investor.regeneron.com/news-releases/news-release-details/two-year-pulsar-trial-results-aflibercept-8-mg-demonstrate/
• 8 Wykoff CC, Garweg JG, Regillo C. et al. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. Am J Ophthalmol 2023; 260: 70-83
• 9 Eter N, Singh RP, Abreu F. et al. YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale. Ophthalmol Sci 2022; 2: 100111
• 10 Regeneron Pharmaceuticals. Two-year Results for Aflibercept 8mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema (June 2023). Im Internet (Stand: 01.03.2024): https://investor.regeneron.com/news-releases/news-release-details/two-year-results-aflibercept-8-mg-pivotal-photontrial/
• 11 Im JHB, Jin YP, Chow R. et al. Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: A systematic review and meta-analysis. Surv Ophthalmol 2022; 67: 1593-1602
• 12 Greenlee TE, Wang VY, Kang H. et al. Consequences of Lapses in Treatment with Vascular Endothelial Growth Factor Inhibitors in Neovascular Age-Related Macular Degeneration in Routine Clinical Practice. Retina 2021; 41: 581-587
• 13 Kertes P, Regillo C, Kaiser PK. et al. TALON, a phase III b study of brolucizumab versus aflibercept in a matched (treat-and-extend) regimen in patients with neovascular age-related macular degeneration: 32-week primary outcomes. Im Internet (Stand: 18.03.2024): https://euretina.org/resource/thirty-two-week-results-from-talon-a-phase-iiib-study-of-brolucizumab-versus-aflibercept-in-a-matched-treat-and-extend-regimen-in-patients-with-neovascular-age-related-macular-degeneration/
• 14 Kessler LJ, Mayer CS, Bagautdinov D. et al. [Bilateral Vasculitis after Single Intravitreal Brolucizumab Injection]. Klin Monbl Augenheilkd 2022; 239: 196-201
• 15 Kessler LJ, Mayer CS, Son HS. et al. [Bilateral vasculitis following intravitreal brolucizumab injection]. Ophthalmologe 2022; 119: 93-97
• 16 Khoramnia R, Figueroa MS, Hattenbach LO. et al. Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD. Graefes Arch Clin Exp Ophthalmol 2022; 260: 1843-1856
• 17 Bodaghi B, Khanani AM, Khoramnia R. et al. Gains in the current understanding of managing neovascular AMD with brolucizumab. J Ophthalmic Inflamm Infect 2023; 13: 51
• 18 Wykoff CC, Brown DM, Reed K. et al. Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients with Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA Ophthalmol 2023; 141: 834-842
• 19 Khanani AM, Aziz AA, Khan H. et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results. Eye (Lond) 2023; 37: 3574-3581
• 20 Li G, Zhu N, Ji A. Comparative efficacy and safety of Faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: A systematic review and meta-analysis of randomized clinical trials. Medicine (Baltimore) 2023; 102: e36370